Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

ge biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the potency, safety and tolerability profile of ANA598, which may not be duplicated in future cohorts at higher doses or future clinical studies of longer duration; (ii) the belief that ANA598 is a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and the ability to use ANA598 in combination with other anti-HCV agents in the future; (iii) the potential for once-daily or twice-daily oral dosing of ANA598; (iv) the ability of Anadys to transition into Phase II studies of ANA598 during 2009; and (v) expectations regarding the evolution of the market for HCV therapies. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies (including those described in this press release) may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues, will have favorable results in future cohorts of the Phase Ib study or future clinical trials, will maintain fast track designation or will receive regulatory approval. In addition, Anadys' results may be
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Patient engagement has become a ... are turning to an assortment of marketing activities ... of this evolving approach to patient engagement, marketers ... engage patients throughout their experiences with a disease ... mapping the patient journey and employing a consumer ...
(Date:7/11/2014)... July 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... announced that the Food and Drug Administration ("FDA"), has ... on RCP,s Investigational New Drug ("IND") application before granting ... the US. Dr. Chris Chapman , ... comments on our IND. When we receive the agency,s ...
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... 11, 2014 As reported by the ... (Weintraub 7/11/14), a significant number of severe adverse events ... issues and even death from the highly-promoted and costly ... the Times report , a regulatory filing revealed ... by patients was almost 14% of prescriptions, up from ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... Tickets at the Sleep Train Amphitheatre in Wheatland, CA. ... that can compare to what the Sleep Train Amphitheatre can ... events and special attractions over the course of its existence ... the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) will ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... ... for driving physician retention. , ... Charlotte, NC (Vocus) June 3, 2009 -- Morehead Associates will ... Physician Retention through Engagement.", , ,Retaining skilled, engaged physicians is critical to the success ...
... everyone. One of the most promising solutions is a ... wellness solution and created a stand alone program for small ... participate in behavior change programs that improve employee health. , ... pay more for employee health care than larger companies. ...
... asthma worse in patients with mild and moderate forms of ... researchers, although it may reduce the response to medications. , ... years, there has been much interest in the possible link ... Associate Professor of Medicine at National Jewish Health. "By studying ...
... , The following statement can be attributed to the American ... The American Chemistry Council (ACC) today welcomed a congressional ... its review of the scientific evidence on the safety of ... , We agree with Reps. Henry Waxman and Bart Stupak ...
... Nancy Pelosi held a press availability with Secretary of Health and ... afternoon. Below are their remarks: , , Speaker ... Secretary to the Speaker,s office. Both of us went to ... course the Secretary went there long after I was there but ...
... PDSG Integrates Data Sharing Product Portfolio , , ... Bulletin Board: PTSC) announced today that, as a result ... business into the data and information sharing solutions market, ... changed its name to Patriot Data Solutions Group, Inc. ...
Cached Medicine News:Health News:Morehead Webinar on Driving Physician Retention through Engagement 2Health News:MyWellSteps(TM) Delivers an Important Key to Healthcare Reform - Wellness Programs for Small Businesses 2Health News:Obesity does not worsen asthma, but may reduce response to medications 2Health News:American Chemistry Council Welcomes Call for Expedited FDA Review of BPA 2Health News:Pelosi Remarks Before Meeting with Secretary of Health and Human Services Kathleen Sebelius 2Health News:Patriot Scientific Corporation Announces Patriot Data Solutions Group 2Health News:Patriot Scientific Corporation Announces Patriot Data Solutions Group 3Health News:Patriot Scientific Corporation Announces Patriot Data Solutions Group 4Health News:Patriot Scientific Corporation Announces Patriot Data Solutions Group 5
Dome shape, extra smooth tip provides safe insertion through wound & manipulation within the eye. 45, 4.0mm from end...
...
...
...
Medicine Products: